Soluble CD27 (sCD27) in the cerebrospinal fluid (CSF) is emerging as a viable biomarker for detecting early multiple sclerosis (MS), and now Wong et al. 1 have studied this biomarker in pediatric MS. Pediatric MS is one of the earliest forms of MS, typically presenting in early adolescence. 2 It is challenging to diagnose and has a highly inflammatory disease course with frequent relapses. 3 Diagnosis can be delayed because of uncertainty about which cases of acute disseminated encephalomyelitis (ADEM) or clinically isolated syndromes (CIS) may ultimately declare themselves as pediatric MS. Diagnosis has relied on a combination of clinical and magnetic resonance imaging (MRI) features, which manifest in the International Pediatric MS Study Group clinical definitions. 4 The search for biomarkers to augment clinical definitions has been challenging. Oligoclonal bands in the CSF have predictive value in optic neuritis cases, for clinically definite MS, with an odds ratio of 3.69 in a recent study. 5 However, the immunopathogenicity of oligoclonal bands is unclear, and the target has been elusive.
CD27 is a co-stimulatory molecule and CD4 and CD8 T-cell activation marker, which interacts with CD70 present on the surface of antigen-presenting cells. CD27 is a tumor necrosis factor receptor (TNFR) family member and interacts with tumor necrosis factor receptor-associated factor (TRAF) family adaptors, specifically TRAF2 and TRAF5, inducing activation of nuclear factor-kappa B (NF-kB) and c-Jun kinase signaling pathways, either in conjunction with T-cell receptor complex (TCR) activation or independently. Its ligand, CD70, is a homotrimeric type II transmembrane glycoprotein expressed on activated dendritic cells, B cells, and T cells, as well as gut epithelia. Engagement of CD27 induces longterm memory of T cells, through Bcl-xL activation and NF-kB activation. CD70 contributes to germinal center formation and B-cell activation including Ig production. Memory T cells have been shown to be increased in pediatric MS and likely play a role in the inciting immunopathogenicity of disease. 6, 7 sCD27 is secreted by T cells after activation through the TCR and was initially discovered as a CSF biomarker for MS by Komori et al. 8 in relapsing and progressive MS patients, indicating a role for T cell-associated inflammation in both stages of disease. More recently, sCD27 in the CSF was shown to be differentially increased in adult CIS patients, eventually diagnosed with MS compared to those who remained monophasic, with a hazard ratio (HR) of 2.4 per 100 U/mL increase of sCD27 (95% confidence interval (CI), 1.27-4.53; p = 0.007). 9 Moreover, higher levels of CSF sCD27 were associated with an increased relapse rate, shorter time to next relapse, and increased number of T2 lesions on baseline MRI in adult patients and a correlation with CSF oligoclonal bands and elevated IgG index.
In children and adolescents with CIS, this biomarker was studied in 94 patients with an acute demyelinating syndrome (ADS), who were stratified into either those with encephalopathy or ADEM-like phenotype and those without encephalopathy or CIS-like. The results mimicked the adult results, showing an HR of 1.8 per 100 U/mL increase in sCD27 levels, p = 0.031, for increasing pediatric MS risk, after adjusting for the presence of oligoclonal bands and MRI lesion load.
This well-conducted study identifies a novel biomarker for disease activity in pediatric patients at the time of their first attack. Further validation and incorporation of this biomarker into prognostic and diagnostic criteria for pediatric MS is needed. The association of sCD27 with T-cell activation and memory cells sheds light on potential early inciting events in pediatric MS, and the CD27-CD70 pathway may be considered as a possible therapeutic target for early relapsing forms of MS.
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